about
Intermittent Atrioventricular Block following Fingolimod Initiation.Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.Neuromyelitis optica spectrum disease with positive autoimmune indices: a case report and review of the literatureCapecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?Central Nervous System Demyelination in a Charcot-Marie-Tooth Type 1A Patient.CNS Demyelination with TNF-α BlockersImmune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literatureMultiple sclerosis and Parkinson's disease: the two faces of neurodegeneration. Report of the first Greek case and review of the literature.The possible effects of the solar and geomagnetic activity on multiple sclerosis.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.Cognitive dysfunction in non-demented patients with Parkinson's disease.The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson's disease.Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis.Subcortical frontal lesions on MRI in patients with motor neurone disease.Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.Corpus callosum infarct associated with combined variants in circle of willis.Frontal lobe dysfunction in amyotrophic lateral sclerosis.CSF biomarker profile and diagnostic value in vascular dementia.Anti-myelin-associated glycoprotein polyneuropathy coexistent with CREST syndrome.The onset of multiple sclerosis in Greece: a single-center study of 1,034 consecutive patients.Spastic paretic hemifacial contracture as a presenting feature of multiple sclerosis.A novel heterozygous mutation in the NOTCH3 gene causing CADASIL.Circulating interleukin-10 and interleukin-12 in Parkinson's disease.Familial Asymmetric Distal Upper Limb Amyotrophy (Hirayama Disease)Lack of association between vitamin D levels and bone mineral density in patients with multiple sclerosisBrugada sign in a multiple sclerosis patient: Relation to autonomic nervous system dysfunction and therapeutic dilemmasBenign Raeder Syndrome Evolving Into Indomethacin-Responsive Hemicranial HeadacheCirculating interleukin-15 and RANTES chemokine in Parkinson’s diseaseStiff person syndrome: avoiding misdiagnosisHereditary neuropathy with liability to pressure palsies: the same molecular defect can result in diverse clinical presentationRecurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review
P50
Q34069400-CDBD2CD4-A63F-43ED-BF4E-7BF29FCDB76EQ34547983-DE31ED2A-EE9C-4F6C-B338-E96C1AC9DD2AQ35504307-0E9FA330-2141-47BC-BCCC-E42F9989D061Q36600571-8D8F42C3-EDC6-4DE7-8FDE-3A690FF007E3Q37423008-98E5C2DB-21FA-40B7-8BA5-378AD1F2DC57Q37719132-7592D14E-7223-4575-A031-CF4A9235EFCAQ38264914-35A7B4FB-6ADA-4FF7-A6E7-BBF5278D646DQ38541861-A2748570-45E7-4AD6-89E5-5E2ADA730003Q39780771-3C9E8E8E-19DE-44BA-B055-C2BD08F7BCE9Q41002593-F9CAACD5-E3B9-41E0-AACE-589577ACCB5EQ45774108-60072549-1879-4515-9E9B-A9CB798C89F4Q45958079-46724BAC-10B8-434D-9D0A-D2D88B19AA15Q46657859-BC73C25E-6F42-4A6E-941C-8648E47BF645Q48441372-8F60E38D-1445-43B9-9246-B4D776686C5EQ48506252-9632076D-1897-4201-9E57-A43753D2EC65Q48537303-B7F8619B-8761-41B1-BCDC-3C03C43D1860Q48676515-6C976C0A-20D0-42BA-BA4A-64E1980048EBQ49174196-0CC88100-BFF5-46CE-B3CA-76676CEECA33Q50260465-B36A315B-3555-4CC0-9FA2-8A985EAFBE18Q51561335-6ADDC6D1-1821-4BC5-861E-374C3BDFE72AQ52097974-DCF7ED20-2D5C-463B-AEEB-FDDAD170F5A5Q53389950-4C1E9AA3-9CD3-43D5-ACBE-5AEA17DED817Q54682442-F7C08556-4B4C-4EB4-ADA8-1AE22353FFBCQ58381679-23A1A57B-F977-4D56-8896-10A7202DE687Q61786706-ECEC01C7-1F16-49CC-9575-BF4F47B91DE3Q63487428-E0F78AB7-E82C-44B8-BEA0-4C3AFD50DFFAQ63487589-0FB7026B-A1FD-4F57-95CC-448F4C81C247Q63487622-8CF77C09-5B78-47E8-B792-9724907B189AQ63487631-FE115DB2-C1EC-44B4-A8F5-51E7B3D7D56BQ63487680-25D5A21A-970B-4FD0-9995-EA2B304E094AQ92394469-6396457B-F4C1-4D66-9545-40970DB4FD41
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisabeth Andreadou
@ast
Elisabeth Andreadou
@en
Elisabeth Andreadou
@es
Elisabeth Andreadou
@nl
Elisabeth Andreadou
@sl
type
label
Elisabeth Andreadou
@ast
Elisabeth Andreadou
@en
Elisabeth Andreadou
@es
Elisabeth Andreadou
@nl
Elisabeth Andreadou
@sl
prefLabel
Elisabeth Andreadou
@ast
Elisabeth Andreadou
@en
Elisabeth Andreadou
@es
Elisabeth Andreadou
@nl
Elisabeth Andreadou
@sl
P106
P1153
23666563700
P21
P31
P496
0000-0002-9634-9631
P569
2000-01-01T00:00:00Z